BTIG analyst Justin Zelin reiterated a Buy rating on Verastem yesterday and set a price target of $20.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Justin Zelin has given his Buy rating due to a combination of factors that highlight Verastem’s strong commercial performance and potential for future growth. The company reported impressive net revenue of $11.2 million in the third quarter of 2025, significantly surpassing both BTIG and market expectations. This success is attributed to the early adoption of their newly approved product, AVMAPKI FAKZYNJA Co-Pack, in treating recurrent KRAS-mutant low-grade serous ovarian cancer, as well as robust payer coverage and effective commercial execution.
Despite a temporary market reaction to the Independent Data Monitoring Committee’s recommendation for a modest increase in patient enrollment for the RAMP-301 study, Zelin views this adjustment as a conservative measure to maintain statistical power rather than a reflection of weaker efficacy. The study remains promising, with encouraging data in both KRAS-mutant and wild-type cohorts. Additionally, Verastem’s VS-7375 shows potential as a best-in-class treatment for G12D, supported by strong efficacy and tolerability data. With a solid execution strategy, upcoming catalysts, and a stable financial outlook, Zelin sees the recent stock pullback as an attractive entry point, reinforcing his Buy rating and $20 price target.
In another report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $15.00 price target.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VSTM in relation to earlier this year.